COMPARATIVE ANALYSIS OF USING VARIOUS SCHEMES OF TREATMENT OF PATIENTS WITH POSTINFARCTION CARDIOSCLEROSIS AND TYPE 2 DIABETES

Authors

  • Bilovol O. M. Kharkiv National Medical University
  • Kravchun P. P. Kharkiv National Medical University
  • Ryndina N. G. Kharkiv National Medical University
  • Rynchak P. I. Kharkiv National Medical University
  • Kadykova O. I. Kharkiv National Medical University

DOI:

https://doi.org/10.21856/j-PEP.2015.2.01

Keywords:

postinfarction cardiosclerosis, type 2 diabetes, ramipril, telmisartan.

Abstract

This article provides a comparative analysis of the different treatment schemes of patients with postinfarction cardiosclerosis and type 2 diabetes through the examination of 68 patients with the specified pathology. As a result of randomization was formed two observation groups: 1 group — 35 patients with postinfarction cardiosclerosis and type 2 diabetes, treated with ramipril 10 mg per day; group 2 — 33 patients with postinfarction cardiosclerosis and type 2 diabetes treated with telmisartan 40 mg a day. Treatment of postinfarction cardiosclerosis in patients with type 2 diabetes mellitus using ramipril and telmisartan showed a positive effect on the structural and functional parameters of left ventricular, ejection fraction, adypokines, fraktalkin and clusterin. Comparative analysis of ramipril and telmisartan using in patients with postinfarction cardiosclerosis and type 2 diabetes did not show significant differences between the studied parameters, which was also confirmed by Cox proportional regression analysis.

References

Atlas SA. J Managed Care Pharmacy 2007;13, 8(B): 9-20.

Wong J, Patel RA, Kowey PR. Progr Cardiovasc Dis 2004;47(2): 116-130.

Seredyuk VN. Prikarpatsky News NTSh. Pulse 2009;4(8): 70-78.

Engeli S. Hypertension 2005;45: 356-362.

Kadoglou NPE, Vrabas IS, Kapelouzou A. Regulatory Peptides 2011;170(1-3): 57-61.

Britton KA, Fox CS. Clin Lipidol 2011;6/1(79-91): 1758-4299.

Walaa MHN, Ashraf IA, Zeinab AH, Dalia HA. EXCLI J 2013;12: 924-932.

Montalescot G, Sechtem U, Achenbach S. Eur Heart J. 2013;34(38): 2949-3003.

McMurray JJ, Stewart S. Eur Heart J. 2002;4(D): 50-58.

The SOLVD Investigators. N Engl J Med. 1991;325: 293-302.

Flather MD, Yusuf S, Kiber L. Lancet 2000;355: 1575-1581.

Fox KM. Lancet 2003;362: 782-788.

Dagenais GR, Pogue J, Fox K, et al. Lancet 2006;368: 581-588.

Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355: 253-259.

McKelvie RS, Yusuf S, Pericak D. Circulation 1999;100: 1056-1064.

Granger CB, McMurray JJ, Yusuf S. Lancet 2003;362: 772-776.

McMurray J, Ostergren J, Swedberg K. Lancet 2003;362: 767-771.

Dahlof B, Devereux RB, Kjeldsen SE. Lancet 2002;359: 995-1003.

Downloads

Published

2021-08-18

How to Cite

Бiловол О. М., Кравчун, П. П., Риндiна . Н. Г., Ринчак П. I., & Кадикова О. I. (2021). COMPARATIVE ANALYSIS OF USING VARIOUS SCHEMES OF TREATMENT OF PATIENTS WITH POSTINFARCTION CARDIOSCLEROSIS AND TYPE 2 DIABETES. Problems of Endocrine Pathology, 52(2), 7-14. https://doi.org/10.21856/j-PEP.2015.2.01

Issue

Section

CLINICAL ENDOCRINOLOGY